Recent preclinical studies have further demonstrated that eEF1A1 degradation via the NEDD4L-mediated ubiquitin–proteasome pathway suppresses tumor angiogenesis by inhibiting endothelial cell proliferation and migration, highlighting its therapeutic potential in antiangiogenic therapy [88]. This evidence concerns the gene EEF1A1 and neoplasm.